Iniparib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Iniparib" in English language version.

refsWebsite

Global rank English rank

6nih.gov

4^th place

4web.archive.org

1^st place

4doi.org

2^nd place

2clinicaltrials.gov

5,225^th place

4,062^nd place

1who.int

195^th place

302^nd place

1biparsciences.com

low place

1parp-inhibitors.com

low place

1reuters.com

49^th place

47^th place

1books.google.com

3^rd place

1dancewithshadows.com

low place

1medpagetoday.com

9,274^th place

5,856^th place

1internalmedicinenews.com

low place

1fiercebiotech.com

low place

8,828^th place

1bloomberg.com

99^th place

77^th place

biparsciences.com

"Iniparib (BSI-201)". Our Privacy PolicyBiPar Sciences. Sanofi-Aventis. Archived from the original on 23 June 2010.

bloomberg.com

Torsoli A, Serafino P (3 June 2013). "Sanofi Ends Iniparib Research". Bloomberg.

books.google.com

Irshad S, Tutt A (2015). "Clinical Trials Investigating PARP Inhibitors as Single Agents". In Curtin NJ, Sharma RA (eds.). PARP inhibitors for cancer therapy. Humana Press. p. 490. ISBN 978-3-319-14151-0.

clinicaltrials.gov

Clinical trial number NCT00938652 for "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer " at ClinicalTrials.gov 2009 to 2012, Primary completion date June 2011
Clinical trial number NCT01082549 for "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer (ECLIPSE) " at ClinicalTrials.gov 2010 to 2014, PCD 2012

dancewithshadows.com

"Sanofi's new drug BSI 201 offers to treat the toughest breast cancer". 3 June 2009. Archived from the original on 2009-10-18. Retrieved 2009-11-17.

doi.org

Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. (January 2012). "Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor". Clinical Cancer Research. 18 (2): 510–23. doi:10.1158/1078-0432.CCR-11-1973. PMID 22128301.
Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (March 2012). "Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro". Clinical Cancer Research. 18 (6): 1655–62. doi:10.1158/1078-0432.CCR-11-2890. PMC 3306513. PMID 22291137.
O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. (January 2011). "Iniparib plus chemotherapy in metastatic triple-negative breast cancer". The New England Journal of Medicine. 364 (3): 205–14. doi:10.1056/NEJMoa1011418. PMID 21208101.
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. (December 2014). "Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer". Journal of Clinical Oncology. 32 (34): 3840–7. doi:10.1200/JCO.2014.55.2984. PMID 25349301.

fiercebiotech.com

"Sanofi breast cancer drug flunks Phase III trial". Fierce Biotech. 28 January 2011.

internalmedicinenews.com

"PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival". 11 October 2010. Archived from the original on 13 July 2011. Retrieved 12 October 2010.

medpagetoday.com

"SABCS: PARP Inhibitor Data Called 'Spectacular'". Dec 2009.

nih.gov

pubmed.ncbi.nlm.nih.gov

Patel A, Kaufmann SH (January 2010). "Development of PARP inhibitors: an unfinished story". Oncology. 24 (1). Williston Park, N.Y.: 66, 68. PMID 20187324.
Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. (January 2012). "Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor". Clinical Cancer Research. 18 (2): 510–23. doi:10.1158/1078-0432.CCR-11-1973. PMID 22128301.
Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (March 2012). "Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro". Clinical Cancer Research. 18 (6): 1655–62. doi:10.1158/1078-0432.CCR-11-2890. PMC 3306513. PMID 22291137.
O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. (January 2011). "Iniparib plus chemotherapy in metastatic triple-negative breast cancer". The New England Journal of Medicine. 364 (3): 205–14. doi:10.1056/NEJMoa1011418. PMID 21208101.
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. (December 2014). "Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer". Journal of Clinical Oncology. 32 (34): 3840–7. doi:10.1200/JCO.2014.55.2984. PMID 25349301.

ncbi.nlm.nih.gov

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (March 2012). "Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro". Clinical Cancer Research. 18 (6): 1655–62. doi:10.1158/1078-0432.CCR-11-2890. PMC 3306513. PMID 22291137.

parp-inhibitors.com

"BSI 201". Parp Inhibitors. Archived from the original on 9 December 2019.

reuters.com

"New breast cancer drugs block cell repair enzyme". Reuters. 2009-05-31.

web.archive.org

"Iniparib (BSI-201)". Our Privacy PolicyBiPar Sciences. Sanofi-Aventis. Archived from the original on 23 June 2010.
"BSI 201". Parp Inhibitors. Archived from the original on 9 December 2019.
"Sanofi's new drug BSI 201 offers to treat the toughest breast cancer". 3 June 2009. Archived from the original on 2009-10-18. Retrieved 2009-11-17.
"PARP Inhibitor Adds Nearly 5 Months to Breast Cancer Survival". 11 October 2010. Archived from the original on 13 July 2011. Retrieved 12 October 2010.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. 2011. p. 68. Retrieved 20 December 2016.